Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo

Sponsor
Assiut University
Study ID
NCT05950542
Status
Unknown

Conditions

  • Vitiligo, Generalized

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The study aims to evaluate the safety and efficacy of the combination of topical baricitinib and 308-nm monochromatic excimer light versus 308-nm monochromatic excimer light alone in treatment of non-segmental vitiligo.

Key Dates

Start date
Sep 10, 2023
Status verified
Jul 2023
Primary completion
Sep 20, 2024
Completion
Dec 30, 2024

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Group A
    Vitiligo lesions on the face will be treated with cream (Olumiant)2mg twice daily and excimer light308nm DEKA, Florence,Italy twice weekly for 12 weeks.
  • Arm: Group B
    Vitiligo lesions on the face will be treated with excimer light308nm (DEKA,F lorence,Italy) only twice weekly for 12 weeks.

Primary Outcome Measure

F VASI score [ Time Frame: 6 months ]

Central Contacts